Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - isoprenaline hydrochloride, quantity: 1 mg - injection, solution - excipient ingredients: disodium edetate; sodium chloride; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - isocipraline is indicated: - for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. - for serious episodes of heart block and adams-stokes attacks (except when caused by ventricular tachycardia or fibrillation) (see section 4.3 contraindications). - for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available (see section 4.3 contraindications). - for brochospasm occurring during anaesthesia. - as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cariodgenic shock (see section 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - isoprenaline hydrochloride, quantity: 1 mg - injection, solution - excipient ingredients: disodium edetate; sodium chloride; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - isocip is indicated: - for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. - for serious episodes of heart block and adams-stokes attacks (except when caused by ventricular tachycardia or fibrillation) (see section 4.3 contraindications). - for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available (see section 4.3 contraindications). - for brochospasm occurring during anaesthesia. - as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cariodgenic shock (see section 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - isoprenaline hydrochloride, quantity: 0.2 mg - injection, solution - excipient ingredients: disodium edetate; sodium chloride; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - isocipraline is indicated: - for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. - for serious episodes of heart block and adams-stokes attacks (except when caused by ventricular tachycardia or fibrillation) (see section 4.3 contraindications). - for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available (see section 4.3 contraindications). - for brochospasm occurring during anaesthesia. - as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cariodgenic shock (see section 4.4 special warnings and precautions for use).

Australia - English - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - isoprenaline hydrochloride, quantity: 200 microgram - injection, solution - excipient ingredients: disodium edetate; sodium chloride; sodium citrate dihydrate; citric acid; hydrochloric acid; sodium hydroxide; water for injections - isocip is indicated: - for mild or transient episodes of heart block that do not require electric shock or pacemaker therapy. - for serious episodes of heart block and adams-stokes attacks (except when caused by ventricular tachycardia or fibrillation) (see section 4.3 contraindications). - for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, are available (see section 4.3 contraindications). - for brochospasm occurring during anaesthesia. - as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolaemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure and cariodgenic shock (see section 4.4 special warnings and precautions for use).

Namibia - English - Namibia Medicines Regulatory Council

aspen pharmacare - isoprenaline hydrochloride - injection - isoprenaline hydrochloride injection 0.2mg/ml

New Zealand - English - Medsafe (Medicines Safety Authority)

sterling winthrop (nz) ltd (now skb nz or sanofi winthrop) - isoprenaline hydrochloride 0.32%{relative}; phenylephrine hydrochloride 0.32%{relative} - aerosol inhaler, metered dose - 0.32%/0.32% - active: isoprenaline hydrochloride 0.32%{relative} phenylephrine hydrochloride 0.32%{relative}

New Zealand - English - Medsafe (Medicines Safety Authority)

inova pharmaceuticals (new zealand) limited - isoprenaline sulfate 100ug - aerosol inhaler, metered dose - 100 mcg/dose - active: isoprenaline sulfate 100ug

New Zealand - English - Medsafe (Medicines Safety Authority)

*** company unknown *** - isoprenaline - oral spray - active: isoprenaline

New Zealand - English - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - isoprenaline - foam - 0.5%w/w - active: isoprenaline